Video

Dr. Neelapu on Interim Results of the Phase II ZUMA-1 Study in DLBCL

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses interim results of the phase II ZUMA-1 study in patients with diffuse large B-cell lymphoma.

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses interim results of the phase II ZUMA-1 study in patients with diffuse large B-cell lymphoma (DLBCL).

ZUMA-1 is a pivotal multicenter trial of KTE-C19, the tested anti-CD19 chimeric antigen receptor T-cell therapy, in patients with refractory DLBCL. According to Neelapu, KTE-C19 is essentially a genetically engineered T-cell product that is trained to recognize CD19 that is expressed on the tumor cells.

At the 2016 ASH Annual Meeting, Neelapu presented the prespecified interim analysis of ZUMA-1, which included patients who had at least 3 months of follow-up after KTE-C19 infusion. The 51 patients with DLBCL in the study were found to yield significant clinical benefit from treatment with KTE-C19. The overall response rate was 76%, and the complete response rate was 47%, says Neelapu.

Related Videos
Fred Saad, CQ, MD, FRCS, FCAHS
Eric Kumar Singhi, MD
Seth Wander, MD, PhD
Lillian L. Siu, MD, FRCPC
Marc Machaalani, MD
Mark Awad, MD, PhD, chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Rasha Cosman, BSc, MBBS, FRACP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Nicholas P. McAndrew, MD, MSCE
Xichun Hu, MD, PhD